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Abstract
Although movement disorders (MDs) are known complications, the exact fre-
quency and severity remains uncertain in patients with classical galactosemia, espe-
cially in children. We determined the frequency, classification and severity of MDs
in a cohort of pediatric and adult galactosemia patients, and assessed the association
with nonmotor neuropsychological symptoms and daily functioning. Patients from
seven centers in the United Kingdom and the Netherlands with a confirmed galac-
tosemia diagnosis were invited to participate. A videotaped neurological examina-
tion was performed and an expert panel scored the presence, classification and
severity of MDs. Disease characteristics, nonmotor neuropsychological symptoms,
and daily functioning were evaluated with structured interviews and validated ques-
tionnaires (Achenbach, Vineland, Health Assessment Questionnaire, SIP68). We
recruited 37 patients; 19 adults (mean age 32.6 years) and 18 children (mean age
10.7 years). Subjective self-reports revealed motor symptoms in 19/37 (51.4%),
similar to the objective (video) assessment, with MDs in 18/37 patients (48.6%).
The objective severity scores were moderate to severe in one third (6/37). Dystonia
was the overall major feature, with additional tremor in adults, and myoclonus in
children. Behavioral or psychiatric problems were present in 47.2%, mostly
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internalizing problems, and associated with MDs. Daily functioning was signifi-
cantly impaired in the majority of patients. Only one patient received symptomatic
treatment for MDs. We show that MDs and nonmotor neuropsychological symp-
toms are frequent in both children and adults with classical galactosemia.
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1 | INTRODUCTION
Classical galactosemia (OMIM: 230400) is an inborn error
of galactose metabolism, caused by a severe deficiency of
the galactose-1-phosphate uridyltransferase (EC 2.7.7.12)
enzyme. After ingestion of galactose in infancy, the accumu-
lation of galactose-1-phosphate and its metabolites results in
multi-organ failure with predominant involvement of the
liver. In particular newborns are susceptible for severe
Escherichia coli sepsis. The mainstay of treatment is a
galactose-restricted and lactose free diet, which is lifesaving
when started early.
Despite this treatment many patients develop long-term
complications.1,2 The most frequent and severe long-term
complications are impaired cognition, speech and lan-
guage deficits, and in women premature ovarian failure.3
Next to these well-known complications, galactosemia is
increasingly being recognized as a neurometabolic disor-
der with significant motor involvement.3–5 In particular
tremor and ataxia have been reported.1,4,6 However, in
most papers, data were collected retrospectively or with-
out formal neurological examination and quantification of
the severity of symptoms.2,6,7 Two more detailed and
recent papers evaluated movement disorders (MDs) in
adult galactosemia patients by direct neurological exami-
nation. Waisbren et al studied 33 adult patients and found
tremor being most frequent (46%), followed by ataxia
(15%), and dystonia (6%).3 Rubio-Agusti et al investi-
gated MDs in 47 adult patients.8 They reported motor
dysfunction in 66%. Tremor was seen in 49%, ataxia in
13%, and a remarkably higher frequency of dystonia
(49%) than earlier reported. Detailed information about
MDs in particular in children with galactosemia is cur-
rently scarce and possible differences between children
and adults are largely unknown.
In galactosemia a high prevalence of depression and anx-
iety has been reported. In patients with (primary) MDs there
is also an increasing awareness of associated nonmotor neu-
ropsychological symptoms.9–11 Whether these symptoms are
secondary to the burden of a MD or part of the phenotype is
still unsolved. It is interesting to evaluate whether the motor
and nonmotor symptoms are associated in galactosemia
patients.3,8
The aim of this study is to systematically determine the
frequency, classification and severity of MDs in a cohort of
adult and pediatric galactosemia patients, and to assess the
association with clinical characteristics, such as treatment
variables. We will also evaluate nonmotor neuropsychologi-
cal symptoms and daily functioning and analyze whether
these are associated with the presence of MDs.
2 | METHODS
Patients were recruited from the metabolic departments of
five nationally endorsed centers of expertise in the Nether-
lands and two in the United Kingdom. All patients, both
children (<18 years) and adults (≥18 years), with a geneti-
cally or enzymatically confirmed diagnosis of classical
galactosemia were invited to participate. Written informed
consent has been obtained from all participants or their offi-
cial caregivers. This study was approved by the medical
ethics committees of the participating centers, and carried
out in accordance with the Declaration of Helsinki.
Self-perceived motor symptoms were evaluated with a
structured interview. Demographic and disease characteris-
tics were obtained by interviewing and/or from patient files.
To determine the presence, classification and severity of
MDs, a standardized videotaped neurological examination
was performed (A.K.). This protocol included walking, pos-
turing tasks, kinetic tasks, and functional tasks such as writ-
ing. The motor phenotype was scored during consensus
meetings using the videos. The expert panel (M.T., T.K.,
R.Z., H.E., A.K.) was briefly informed about the clinical his-
tory and self-reported symptoms. The dominant and any
associated MD types were identified. Severity of each MD
was determined with the Clinical Global Impression severity
scale (CGI, a 7-point Likert scale, higher scores indicate a
more severe MD).12
Adaptive and daily functioning and psychiatric and
behavioral problems were assessed with age-specific vali-
dated Dutch and English questionnaires. In children we
assessed adaptive functioning with the Vineland Adaptive
Behavior Scale,13 and scores were transformed in a
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developmental age equivalent. Subsequently, the percentage
of age-appropriate functioning (developmental age/biologi-
cal age × 100%) was determined. Daily functioning in adults
was evaluated with the Health Assessment Questionnaire
(HAQ),14 providing a Functional Disability Index (FDI,
range 0-3, higher scores indicating more disability), and with
the Sickness Impact Profile (SIP68, range 0-68, higher score
indicating more disability).15 The presence of various
domains of psychiatric and behavioral problems were identi-
fied with age-appropriate versions of the Achenbach ques-
tionnaires, using both a self-report and proxy version (Child
Behavior Checklist and Youth Self Report, Adult Behavior
Checklist, and Adult Self report).16–18
Statistical analyses were carried out using SPSS version
23. Univariate logistic regression was used to calculate odds
ratios for MD presence according to clinical or demographic
characteristics. To assess differences in MD frequencies, the
Fisher's exact test was used. Differences in continuous vari-
ables between patients with and without MDs were analyzed
with the Independent samples t test or Mann-Whitney U test,
depending on normality of the data.
This study was approved by the medical ethics commit-
tees of the participating centers. All procedures followed
were in accordance with the ethical standards of the respon-
sible committee on human experimentation (institutional and
national) and with the Helsinki Declaration of 1975, as
revised in 2000.
Written informed consent has been obtained from all par-
ticipants included in the study or their official caregivers.
This article does not contain any studies with human or
animal subjects performed by the any of the authors.
3 | RESULTS
Thirty seven patients were recruited (15 males, 22 females),
from 29 different families (eight pairs of siblings). The partici-
pation rate was 70% (37/53). The cohort contained 19 adult
patients (mean age 32.6 years) and 18 children (mean age
11.0 years). Four of the adult patients reported here, were also
included in the study by Rubio-Agusti et al8 Table 1 presents
the demographic and disease characteristics.
3.1 | Self-perceived motor symptoms
The structured self-report revealed subjective motor symp-
toms in 19/37 patients (51.4%, 5 children, 14 adults). Twelve
of them reported problems with fine motor tasks (writing
and closing buttons) as well as gross motor skills (running
or balance), four had difficulties only with fine motor tasks,
and three patients only gross motor problems. The rate of
self-reported motor problems was similar to the frequency of
MDs observed with the video assessment, but these
frequencies do not comprise exactly the same patients. Three
patients who were found to have MDs based on the video
examination did not report motor problems themselves. On
the other hand, four patients reported motor symptoms them-
selves (one intermittent trembling of the hands, three prob-
lems with gross motor skills) while no MDs were detected
during the video examination.
In 7/19 (36.8%), all adults, these symptoms were reported
progressive. The majority of patients (78.9%) indicated that
TABLE 1 Demographic and disease characteristics (n = 37)
Gender
Male 40.50%
Female 59.50%
Age group
Children (<18y) 48.60%
Adults (≥18y) 52.40%
Age (years) mean (SD)
Adults 32.6y (8.4)
Children (<18y) 11.0y (5.4)
Country of residence
Netherlands 81.10%
United Kingdom 18.90%
Time of diagnosis
Median age in days (IQR) 8 (15)
Early (within 2 weeks of age) 73%
Late (after 2 weeks of age) 27%
Reason for diagnosis
Clinical symptoms 75.70%
New-born screeninga 13.50%
Sibling screen 10.80%
Reported dietary adherence
Strict adherence 83.80%
Minor variability in adherence 13.50%
Longer nonadherent periods 2.70%
Educational level adults
Special needs or primary school 4/19 (21.1%)
Lower vocational education 4/19 (21.1%)
Secondary education 10/19 (51.6%)
Higher education 1/19 (5.3%)
Motor milestones
In time 67.60%
Delayed 32.40%
Abbreviations: IQR, interquartile range.
Values represent frequencies in percentages. Age is represented as mean (SD),
and age at diagnosis as median (IQR).
aNew born screening for galactosemia was introduced in The Netherlands
in 2007.
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their motor symptoms had already started before the age of
10 years, in two it started as between 10 and 20 years, in
one patient between 20 and 40 years, and in one after the
age of 40.
3.2 | Movement disorder assessment
Based on videotape evaluation by the expert panel, MDs
were present in 18/37 patients (48.6%). In the pediatric
group the total frequency of MDs was 38.9% and in adults
57.9% (Fisher's exact test P = 0.330). In the majority
(10/18) more than one MD was present simultaneously.
MDs were predominantly scored as mild (maximal CGI 3),
but in one third (6/18) MDs were at least moderate (CGI
4-7). Table 2 presents the type, severity, and distribution
of MDs.
Dystonia was most frequently observed (3 children,
9 adults). In all but one dystonia was the predominant MD
type. The dystonic symptoms were mild in the majority of
cases, but in three patients classified as moderate (CGI 4),
and in one as severe generalized dystonia (CGI 6). The
upper limbs were most often affected (n = 9) and five
patients had a torticollis. When only the upper limbs were
affected, dystonia was often action-specific, while in case of
a generalized or segmental distribution including the neck or
trunk a more persistent pattern was seen.
Tremor was the second most common MD, present in
1 child and 5 adults. The severity of tremor ranged from
minimal (CGI 2) to marked (CGI 5). The tremor was limited
to the upper limbs in most patients, in three the head was
also tremulous. In one patient a jaw tremor was observed.
Tremor was frequently seen in combination with dystonic
features (4/6). In three patients the tremor could be charac-
terized as a fast bilateral combined intention and action
tremor, in one as only a mild intentional tremor. In two other
patients the tremor was more distal, postural, fast, and with a
TABLE 2 Details of the observed MDs by video examination
Patient
(sex, age)
Overall
CGI
Predominant MD Associated MD
Other
neurological signsType CGI Type CGI
M, 2y 2 Stereotypies 2 1 Hemi spasticity R
M, 9y 4 Dystonia: UL (R&L), N, persistent 4 Chorea: G 3
M, 11y 3 Dystonia: UL (L > R), action specific 3 Tics, stereotypies 2 Mirror movements
M, 13y 3 Ataxia: UL (R&L) 3 Myoclonus: UL (R&L) 3
M, 13y 3 Dystonia: T, UL (R&L), action specific 3 Myoclonus: T & UL (R&L) 2 Mirror movements
F, 16y 4 Tremor: UL (L > R): action & intention,
fast, small amplitude
4 Myoclonus: UL (R&L) 2
M, 17y 2 Myoclonus: G 2 1 Mirror movements
F, 19y 5 Tremor: UL (R&L): action & intention,
fast, large amplitude
5 Dystonia: N & UL (R&L), action-specific 2
F, 23y 2 Dystonia: N, persistent 2 1
F, 24y 2 Tremor: UL (R&L): postural, fast, small
amplitude
2 Ataxia: UL (R&L) 2
F, 25y 6 Dystonia: G, persistent 6 Ataxia:: UL, LL, gait 3
M, 30y 2 Dystonia: UL (L), action specific 2 Tics, stereotypies 2
F, 31y 2 Dystonia: UL (R), persistent 2 1
M, 35y 3 Dystonia: N&T, persistent 3 Tremor: UL (R): intention, fast, small
amplitude
2
F, 40y 4 Dystonia: UL (R > L), N, persistent 4 Tremor: UL (R&L), H: action &
intention, slow, large amplitude
4
F, 43y 3 Dystonia: UL (L > R), action specific 3 1
F, 44y 2 Dystonia: UL (L), action specific 2 1
F, 50y 4 Dystonia: UL (R > L), N, persistent 4 Tremor: UL (R > L), H, J: rest &
intention, slow, large amplitude
Ataxia: UL (R&L)
3
Abbreviations: MD, movement disorder; CGI, Clinical Global Impression severity scale, values represent the following: 1, no MD; 2, minimal signs of a MD; 3, mild
MD; 4, moderate MD; 5, marked MD; 6, severe MD; 7, among most extremely affected patients.
UL, upper limb(s); LL, lower limb(s); N, neck; H, head; T, trunk; G, generalized; J, jaw; R, right; L, left.
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small amplitude. In one patient a slower rest tremor was
seen, with larger amplitude.
Myoclonus was found in four children. Myoclonus was
mild and in only one patient generalized and the dominant
MD type. In the others it was associated with either dysto-
nia, tremor, or ataxia and affected the upper limbs, mostly
distal. Myoclonus was in all cases provoked by action and
not stimulus sensitive.
Other MDs and motor symptoms included ataxia, tics,
stereotypies, and spasticity. In four patients, one child and
three adults, ataxia was seen and in three of them ataxia was
not the dominant feature but associated with dystonia or
tremor. Ataxic signs consisted of upper limb dysmetria and
dysdiadochokinesis in three patients and in one there was a
more extended picture with involvement of lower limbs and
gait ataxia as well. Three patients had tics or stereotypies, all
in the context of psychomotor retardation or autism. One
boy with a history of intracranial bleeding in infancy had
spasticity. Further, speech problems were frequent (59.5%),
consisting of word-finding difficulties or stuttering rather
than dysarthria. One patient had a spasmodic dysphonia.
In our cohort there was only one patient, suffering from
generalized dystonia and ataxia, who received specific MD
treatment (trihexyphenidyl, botulinum toxin injections, and a
lycra suit). Ten patients had supportive therapy such as phys-
iotherapy or occupational therapy at some point in their lives.
3.3 | Nonmotor findings
Eight patients (21.6%) had at least one psychiatric diagnosis
in their past and were all treated for this. Four patients were
diagnosed with an autism spectrum disorder, three with
attention deficit hyperactivity disorder (ADHD), two with a
depression, one had generalized anxiety, and one had had a
psychotic episode.
The Achenbach questionnaires revealed behavioral prob-
lems on at least one of the evaluated domains in 47.2%.
Internalizing problems were most frequent; 38.9% had a
deviant score (either borderline range (n = 3) or clinical
range (n = 11)) when assessed by proxy-report (available in
36 patients). When assessed with self-report (available in
26 patients), internalizing problems were found in 26.9%.
The most contributing subdomain was withdrawn/depressed,
abnormal in 33.3% respectively 30.8% (proxy and self-
report), followed by anxious/depressed, abnormal in 16.7%
and 19.2%. See supplementary Table 1, Supporting Informa-
tion for T-scores on the different domains.
3.4 | Daily functioning
The mean level of adaptive functioning in the children in
our cohort was only 68.8% of their age-appropriate
functioning. All three subdomains (communication, daily
activities, and social skills) were affected, with the daily
activities showing the largest delay. (Data shown in Supple-
mentary Table 2).
The median FDI of adult patients was 0.06 (interquar-
tile range [IQR] 0.41); slightly higher than the median
score of 0.00 in corresponding age groups in the general
population.14 A few patients had considerably more func-
tional impairment; the highest score was 2.50. Overall,
almost half of the adult patients (47.4%) had some form of
disability (FDI > 0), a higher percentage than in corre-
sponding age groups in the general population (8.5% to
25.0% in ages 30 to 50).14 The median score on the
SIP68, also assessing impact on daily life, was 4.5 (IQR
9). No normative values are available, but the level of dis-
ability in this cohort was lower than reported for patients
with acute traumatic brain injury (mean SIP68 score
15.6 ± 11.5)19 or acute stroke (mean score 41.2 ± 11.7)20
However, again we saw some outliers in our cohort with
considerable disability (highest score 30). Furthermore,
6/19 adult patients (31.6%) had to use an aid or device for
their daily activities, such as a wheelchair, bath seat, or a
tray to carry things.
3.5 | Factors associated with the presence
of MDs
We performed a univariate logistic regression analysis to
identify whether clinical factors, such as age at diagnosis
or dietary adherence, are associated with the presence of
MDs (Table 3). MDs were not significantly more frequent
among patients diagnosed late (later than 2 weeks of age
[cut off based on Ref. 21]) than those diagnosed within
2 weeks of age We also found no differences in MD fre-
quency between groups with higher or lower dietary adher-
ence. However, a delay in motor milestones was strongly
associated with the presence of MDs (odds ratio 28.29,
P = 0.003).
MDs were found more frequently in children receiving
special education than in those attending regular education
(80.0% vs 22.2%), and more frequently in adults who were
unemployed than in those who had a paid job (88.5% vs
40.0%), although these differences did not reach statistical
significance (P = 0.055 and P = 0.060).
We found a significant association between MDs and
internalizing behavioral problems; MDs were present in
71.4% vs 31.8% of the patients respectively with (n = 14)
and without (n = 22) internalizing problems (Fisher's exact
P = 0.023). This association with MD presence was also
found for the subdomain anxious/depressed, MDs were
observed in 100% (n = 6) vs 36.7% (n = 30) in patients
respectively with and without these psychiatric problems
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(Fisher's exact P = 0.006). The age- and sex-adjusted
T-scores for internalizing problems, the anxious/depressed
subdomain, and total behavioral problems (proxy reports)
were significantly higher in patients with MDs than in those
without (Supplementary Table 1).
When assessing adaptive functioning in children, the
score on the communication domain differed most and sig-
nificantly between patients with and without MDs (68.5% vs
95.5%, P = 0.009). The scores on the other two subdomains
and the total score were also lower in children with MDs,
not reaching statistical significance. (Supplementary
Table 2) The adult patients with MDs had a somewhat
higher FDI than those without (median scores 0.13 vs 0.00),
but this difference was not significant (Mann-Whitney U
P = 0,304). The same is true for the SIP68 score; patients
with MDs had a slightly higher median SIP68 score (7.5 vs
3.5, Mann-Whitney U P = 0.109).
4 | DISCUSSION
This is the first comprehensive study reporting a systematic
and detailed evaluation of MDs together with nonmotor neu-
ropsychological symptoms and the impact on daily function-
ing in both children and adults with classical galactosemia.
MDs were found in almost half of the patients. This fre-
quency is in line with the earlier reports in adults (45 and 66%)
(3.8). The MD prevalence could be an overestimation since
there might have been a selection bias; patients suffering from
MDs may be more inclined to participate in research addressing
this topic. The participation rate of our study was relatively
high (70%), thereby reducing this possible selection bias. In
respect of the prevalence and severity of MDs we found, it is
remarkable that only one patient in our cohort received specific
MD treatment.
Dystonia and tremor were the major MD types in adults,
which is in accordance with the dominant MD types
reported by Rubio-Agusti et al.8 Similar to what is known
for other inborn errors of metabolism (IEM) with MDs,22 the
majority of patients had a combined MD phenotype with dif-
ferent MD types being present simultaneously.
One of the strengths of the present study is the inclusion
of both children and adults, allowing us to demonstrate
remarkable differences in MD types. Dystonia and myoclo-
nus dominated the phenotype in children, while in adults no
myoclonus was detected. This suggests evolution of MDs
over time. Possibly, MD appearance in childhood is influ-
enced by development, immaturity, and ongoing myelina-
tion of the central nervous system (CNS), while later in life
the MDs evolve to a more tremulous appearance. It would
be interesting to see whether a similar difference between
children and adults is seen in other IEM with MDs.
Next to the video assessment, we interviewed patients
about self-perceived motor symptoms. We found less discrep-
ancy between the self-report and the expert evaluation than in
earlier reports.8 The majority of patients in our study indicate
that their motor symptoms started in childhood, but later
beginning was also described. Almost 40% of the patients
with MDs report their motor symptoms to be progressive,
remarkably only reported by adults. A limitation of this study
is that data on the course of symptoms were collected retro-
spectively and were self-reported. Longitudinal studies are
required to further clarify when MDs occur and whether these
are indeed progressing or evolving in time.
It is not well understood why some galactosemia patients
develop a severe neurological phenotype and others do not.
In many IEM an early diagnosis and treatment is very
important for the clinical (neurological) outcome. However,
in our cohort this association was not found. This is in accor-
dance with earlier studies in galactosemia.1,8,23 It seems that,
although obviously of undisputed importance, early
TABLE 3 Associations of clinical variables with the presence
of MDs
Frequency
of MDs OR (95% CI) P-value*
Male vs female 53.3% vs 45.5% 1.37 (0.37-5.12) 0.638
Adults vs children 57.9% vs 38.9% 2.16 (0.58-8.04) 0.251
Late (>2wks) vs
early diagnosis
(and treatment)
60.0% vs 44.4% 1.98 (0.43-8.20) 0.404
Some dietary
inaccuracies vs
strict dietary
compliance
50.0% vs 48.4% 1.07 (0.19-6.13) 0.942
Delayed motor
milestones vs
normal motor
development
91.7% vs 28.0% 12.25 (1.08-138.99) <0.001
Speech problems
vs no speech
problems
59.1% vs 33.3% 2.89 (0.74-11.36) 0.129
Fertility problems
vs no fertility
problems
(women)
50.0% vs 66.7% 0.50 (0.04-6.55) 0.597
Special education
vs normal
education
(school
children)
80.0% vs 22.2% 14.00 (0.94-207.60) 0.055
Currently
unemployed vs
employed
(adults)
87.5% vs 40.0% 10.50 (0.91-121.39) 0.060
Abbreviations: CI, confidence interval; MD, movement disorders; OR, odds
ratio.
*P-value based on univariate logistic regression analysis.
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initiation of treatment does not always prevent MDs. More-
over, in our study there were two pairs of siblings of whom
the youngest were diagnosed and treated from day one and
had much more severe MDs than the late diagnosed older
sibs. This was also described within a family reported by
Hughes et al.6 Strict dietary adherence also cannot prevent
MDs. Dietary adherence was very high in our patient group,
but patients who had noncompliant periods did not have
more MDs. Too strict dietary regimens with over-restriction
of galactose might even have negative effects. This hypothe-
sis has also been suggested by Knerr et al,24 and similar phe-
nomena were also described in other IEM, like urea cycle
defects.25 These findings might be explained by accumula-
tion of toxic metabolites on one hand, and lack of relevant
(intermediary) metabolites on the other hand. Based on cur-
rent knowledge, we assume that both ends of the spectrum,
late/no dietary treatment as well as a very restricted diet,
would not lead to optimal (motor) functioning.
In our study we found an association between a history
of delayed motor milestones and the occurrence of MDs.
This is an important finding, as it can serve as a “red flag.”
We advise extra alertness for the occurrence of MDs in chil-
dren with galactosemia who have a delayed motor develop-
ment. Based on our results, the occurrence of MDs seems to
be based on an individual susceptibility rather than on treat-
ment characteristics. Our findings might indicate that
patients with MDs have a more severe phenotype in general,
as we also observed a trend that MDs were more frequent in
patients with speech problems, children who attend special
education and in adults who are unemployed. Although we
did not demonstrate statistically significant differences for
these parameters, the found differences are of reasonable
magnitude and should be interpreted in the light of the rela-
tively small sample size. Despite lacking statistical power,
the differences might very well be relevant.
Next to MDs, a high percentage of patients in our study had
behavioral or psychiatric problems (47.2%), associated with the
presence of MDs. Internalizing symptoms such as depression
and anxiety, were most frequent (38.9%). This is in accordance
with earlier reports on psychiatric comorbidity in galactosemia
with high rates of anxiety and depression.3,8 It is interesting to
speculate whether these symptoms are a secondary phenome-
non to physical or cognitive disability or if they are part of the
disease itself. In recent years it has become clear that nonmotor
neuropsychological symptoms form an integral part of several
primary MDs such as idiopathic cervical dystonia or dopa-
responsive dystonia.9,10 The fact that in our study psychiatric
and behavioral symptoms were associated with MDs and were
often co-occurring outlines the possibility that in galactosemia
there might also be a common pathophysiological pathway
affecting both motor and nonmotor circuits. Unfortunately, in
our study we had no electrophysiological registrations or
magnetic resonance imaging (MRI) or neurotransmitter imag-
ing data available. To further elucidate the pathophysiology of
MDs and neuropsychological symptoms in patients with galac-
tosemia, it is important to incorporate the results of these diag-
nostic tests and clinical data in future studies.
Impairment in daily and adaptive functioning was com-
mon in our cohort. Patients with MDs had lower levels of
adaptive functioning; especially the communication domain
appeared associated with MDs. To improve the level of
functioning of our patients, MDs are important to take into
account and should be considered for symptomatic treatment
and supportive therapies.
In conclusion, hyperkinetic MDs are frequent in both
children and adults with galactosemia. We found remarkable
differences in the clinical presentation between children and
adults. The occurrence of MDs seems to be based on an indi-
vidual susceptibility rather than treatment characteristics.
Longitudinal studies are needed to further elucidate the
evolvement of MDs. We demonstrated an association
between MDs and nonmotor neuropsychological symptoms
and a lower level of daily functioning. Based on the results
of our study, we recommend an increased awareness of both
MDs and nonmotor neuropsychological symptoms in
patients with galactosemia. When applicable, treatment of
MDs should be considered. Patients would benefit from reg-
ular and detailed neurological and neuropsychological
assessments; the inclusion of these assessments in galacto-
semia guidelines is supported by this research.
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